Takeda Submits New Drug Application For The Next DPP-IV Inhibitor Alogliptin

Takeda Pharmaceutical Company Limited announced today that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

Discovered by Takeda San Diego, Inc., alogliptin was designed to selectively inhibit DPP-4 taken orally once daily.
DPP-4 inhibitors are a new class of oral agents for the treatment of type 2 diabetes, which slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). The incretins play a major role in regulating blood glucose levels and may have the potential to improve pancreatic beta-cell function.

The NDA submission was supported by six Phase 3 clinical trials involving over 2,000 patients conducted in 220 centers worldwide. The safety and efficacy of alogliptin was studied as a once-daily monotherapy adjunct to diet and exercise and as an add-on therapy to other antidiabetic medications including sulfonylureas, metformin, thiazolidinediones (TZDs), and insulin. In the studies, alogliptin was associated with statistically significant reductions in hemoglobin A1c, which reflects average blood glucose concentration over the previous two to three months. Alogliptin was generally well-tolerated and weight neutral. There was no increase in hypoglycemia compared to placebo.

"The NDA submission for alogliptin is a significant milestone for Takeda, as it has the potential to position us as one of the global leaders in diabetes treatment," said Yasuchika Hasegawa, president of Takeda. Our hope is that alogliptin will become an important treatment option for patients with type 2 diabetes and the healthcare providers who treat them."

GLP-1 and GIP are produced by the digestive tract in response to food, and regulate glucose balance, primarily by stimulating glucose-dependent insulin secretion. In addition, GLP-1 suppresses pancreatic glucagon secretion and subsequent liver glucose production, enhances glucose disposal, slows gastric emptying, and elicits satiety, a feeling of fullness.

===========================

Advertisement
Dr. Philip A. Wood has written a book for healthcare professionals and students of medicine, nursing, pharmacy, and graduate studies, as well lay people interested in understanding the influences of genetics, nutrition, activity level and drugs on diseases associated with excess fat such as obesity, insulin resistance, metabolic syndrome and type 2 diabetes. The book is composed of short, readable chapters with helpful figures to further explain the mechanisms discussed. For further information please click here.
https://www.amazon.com/exec/obidos/tg/detail/-/0674019474/qid=1132176956/sr=8-1/ref=pd_bbs_1/002-7853569-1175265?v=glance&s=books&n=507846